COMMUNIQUÉS West-GlobeNewswire

Trevi Therapeutics to Participate in Upcoming September Conferences
03/09/2026
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
03/09/2026
- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates [...]
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
03/09/2026
Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ET NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and [...]
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
03/09/2026
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
Amwell® receives Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for addressing healthcare fragmentation
03/09/2026
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of technology enabled care, has received Frost & Sullivan's 2026 United States Technology Innovation Leadership Recognition in the [...]
Kraig Biocraft Laboratories Highlighted by Tech Times for Advancing Spider Silk from Science Fiction Toward Commercial Reality
03/09/2026
Feature Explores the Real Biology Behind Recombinant Spider Silk and the Scientific Case for Kraig Labs' Production Platform ANN ARBOR, Mich., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB [...]
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/09/2026
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of [...]
Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials
03/09/2026
Cette acquisition apporte au réseau de développement clinique précoce de Fortrea des compétences bioanalytiques dédiées et une capacité accrue alors que Worldwide poursuit sa stratégie visant à renforcer ses activités [...]
Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026
03/09/2026
SHANGHAI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced today that its “AI + Chronic Care” [...]
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
03/09/2026
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly [...]
Tensive to receive €20 million from EIB to commercialize bioresorbable breast implant
03/09/2026
European Investment Bank (EIB) convertible loan will help fund REGENERA™ development, CE marking, manufacturing scale-up and commercialization Follows positive 12-month pivotal trial data in July First EU regulatory [...]
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
03/09/2026
STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that it will participate in upcoming investor conferences in [...]
Commure Ambient AI Achieves Class I Certification and MHRA Registration
03/09/2026
AI-Powered Clinical Documentation Self-Certified for Immediate UK and EU Deployment MOUNTAIN VIEW, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Commure today announced that Commure Ambient AI , its widely deployed AI [...]
ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury
03/09/2026
The EIGER study will assess the safety and preliminary effectiveness of the investigational ARC-IM ® System to restore mobility after both subacute and chronic spinal cord injury ARC-IM is an implanted neuromodulation [...]
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
03/09/2026
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai [...]
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
03/09/2026
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese ( [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
02/09/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026
02/09/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
02/09/2026
Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ( [...]

Pages